Dear editor,

Tomlins and colleagues recently reported in this journal the clinical features of 95 sequential hospitalised patients with novel coronavirus 2019 disease (COVID-19) in the first UK cohort.[@bib0001] Interestingly, consistent with the evidence supporting the use of CURB-65 as a predictor of mortality secondary to community acquired pneumonia (CAP), non-survivors had a significantly higher CURB-65 score versus survivors (2.5 versus 1 respectively).

The CURB-65 is a severity score for CAP, comprising 5 variables, attributing 1 point for each item: new onset confusion; urea \>7 mmol/L; respiratory rate ≥30/minute, systolic blood pressure \<90 mmHg and/or diastolic blood pressure ≤60 mmHg; and age ≥65 years.[@bib0002] It has been extensively validated to predict 30-day mortality in CAP,[@bib0003] and divides patients into 3 groups: score 0--1: low risk of 30--day mortality (0.7--3.2%); score 2: intermediate risk (13%) and score 3--5: high risk of 30--day mortality (17--57%). The Infectious Diseases Society of America / American Thoracic Society and the British Thoracic Society guidelines suggest that patients with CURB-65 scores of 0--1 are at low risk of death and thus may be managed as outpatients.[@bib0004] ^,^ [@bib0005] However, whether CURB-65 can be applicable to COVID-19 patients for the decision of outpatient treatment is still unknown.

Here, we describe a retrospective single-centre study assessing the performance of the CURB-65 to predict the risk of unfavourable outcome. Hospitalized patients aged 18 or over diagnosed with COVID-19, based on positive SARS-CoV-2 real-time reverse transcriptase-polymerase chain reaction on nasal swabs, and/or typical abnormalities on chest computed tomography (CT) were included in the study. Patients were excluded if they were directly admitted to the intensive care unit (ICU). Their baseline demographics, co-morbidities, clinical symptoms, vital signs, and laboratory results on admission were retrospectively collected. CURB-65 scores were calculated retrospectively. A poor outcome was defined as the need of mechanical ventilation (non-invasive ventilation (NIV) and/or high flow nasal cannula (HFNC) and/or invasive mechanical ventilation) and/or death, whichever occurred first, within the 14 days following admission. The association between the CURB-65 and the outcome was assessed by a univariable Cox proportional hazard regression model to calculate hazard ratios (HR) and their 95% confidence intervals (95%CI). The study was approved by the local institutional review board (IRB 00006477).

A total of 279 patients hospitalized between March 15^th^ and April 14^th^, 2020 were included in this study. Their baseline characteristics at admission are described in [Table 1](#tbl0001){ref-type="table"} . According to the CURB-65, 171 (61.3%) patients were considered at low risk (CURB-65 0--1), 66 (23.7%) at intermediate risk (CURB-65=2), and 42 (15.1%) had high risk of 30-day mortality (CURB-65 3--5). During the study period, 88 (31.5%) patients had poor outcome: 48 (17.2%) were admitted to ICU (28 had NIV and/or HFNC, 27 had mechanical ventilation, following NIV and/or HFNC for 7, and 11 patients died within the 14 days) and 40 (14.3%) patients died without being admitted to ICU, leading to 51 (18.3%) deaths within the 14 days following admission.Table 1Baseline characteristics and outcomes of the study population according to the CURB 65 (N=279)Table 1Overall (N=279)CURB-65*P*0--1 N=1712 N=663--5 (N=42)Age, mean (SD)64.8 (16.1)57.3 (14.4)75.6 (11.6)78.2 (9.5)\<0.001Male sex183 (65.6)107 (62.6)45 (68.2)31 (73.8)0.342Diabetes77 (27.6)39 (22.8)22 (33.3)16 (38.1)0.068Hypertension131 (47.0)61 (35.7)39 (59.1)31 (73.8)\<0.001**CURB-65 features** Confusion23 (8.2)0 (0)8 (12.1)15 (35.7)\<0.001 Urea \>7 mmol/L103 (36.9)10 (5.8)52 (78.8)41 (97.6)\<0.001 Respiratory rate\>30/min59 (21.1)25 (14.6)9 (13.6)25 (59.5)\<0.001 Hypotension22 (7.9)3 (1.8)6 (9.1)13 (31.0)\<0.001 Age \>65 years145 (52.0)47 (27.5)57 (86.4)41 (97.6)\<0.001**Other clinical features**Time from symptom onset to admission, (days)6.76 (4.80)7.3 (5.0)6.9 (4.5)3.4 (3.4)0.001 Respiratory rate (/minute)26.2 (6.7)25.2 (6.1)25.1 (6.0)31.5 (7.8)\<0.001 Body temperature \>38°C110 (39.4)71 (41.5)23 (34.8)16 (38.1)0.630 Cough190 (68.1)129 (73.7)39 (59.1)22 (52.4)0.003 Dyspnoea198 (71.0)126 (37.7)39 (59.1)33 (78.6)0.043 Myalgia58 (20.8)43 (25.1)8 (12.1)7 (16.7)0.067 Diarrhoea55 (19.7)41 (24.0)9 (13.6)5 (11.9)0.077**Biological features** Lymphocytes count (G/L)1.2 (1.0)0.7 (2.5)1.0 (0.6)1.0 (0.7)0.038 C-reactive protein (mg/L)126.3 (91.11)117.0 (86.1)126.1 (94.2)164.2 (98.1)0.013 Creatinine level (µmol/L)108.2 (75.7)84.1 (41.6)134.7 (105.2)164.1 (95.1)\<0.001 SGOT (U/L)71.2 (101.9)65.6 (49.4)58.7 (38.6)108.4 (224.5)0.033 SPOT (U/L)45.8 (59.1)47.0 (43.5)32.79 (24.6)59.73 (114.1)0.078 D-dimers (mg/L)3421.5 (7303.8)3229.8 (7209.2)3662.21 (7544.5)3737.0 (7639.4)0.945 Us Troponin I (ng/L)72.7 (421.9)21.5 (43.8)46.3 (63.1)301.3 (1016.1)0.009 Ferritin (mg/L)1465.3 (1584.2)1485.8 (1836.6)1309.3 (1115.2)1585.3 (1303.5)0.824**Outcome** Favourable191 (68.5)135 (78.9)42 (63.6)14 (33.3)\<0.001 Unfavourable88 (31.5)36 (21.1)24 (36.4)28 (66.7)\<0.001  HFNC or NVI28 (10.0)13 (11.4)10 (29.4)5 (26.3)0.024  Mechanical ventilation27 (39.1)19 (16.2)5 (14.7)3 (15.8)0.977  Deceased51 (18.3)15 (8.9)15 (24.2)21 (53.8)\<0.001[^1]

In the Cox proportional hazard model, the CURB-65 was strongly associated with a poor outcome (HR 1.84, 95%CI 1.10--3.09, *P*=0.020 for a CURB-65 of 2 compared to 0--1; and HR 4.18, 95% CI 2.54--6.86, p\<0.001 for a CURB-65 of 3--5 compared to 0--1; *P ~for\ linear\ trend~* \<0.001). However, among patients with a CURB-65 of 0--1, thus considered at low risk, 36/171 (21.1%) had a poor outcome: 27 (15.8%) were transferred for ICU for HFNC and/or NIV (N=13), and/or invasive mechanical ventilation (N=19), and 15 (8.8%) patients died within the 14 days following admission ([Fig. 1](#fig0001){ref-type="fig"} ).Fig. 1Description of the outcome according to the CURB-65 (N=279).Fig 1

Our results showed that the CURB-65 is associated with an unfavourable outcome, and thus its application as a severity score for COVID-19 might be promising. However, while the majority of our patients would have been considered at low risk of 30-day mortality according to this severity score, more than 20% of them had a poor outcome. Our study suggests that the applicability of CURB-65 to guide the decision of inpatient or outpatient care is scarce, as it does not safely identify patients who could be managed as outpatients.

In studies of CURB-65 in the clinical practice of CAP, many patients with low CURB-65 scores are not suitable for outpatient treatment because many factors are not incorporated in the score, including hypoxemia requiring oxygen therapy, unmet social needs[@bib0006]. In addition, this score also appears to underestimate severity in young patients with CAP. Those limitations might also apply to COVID-19, whose epidemiology and severity also differ from CAP. COVID-19 is a systemic disease, and its severity might be due to virus-activated "cytokine storm syndrome", exacerbated inflammatory responses.[@bib0007] Many known risk factors, such as cardiovascular history, D-dimers, Interleukin-6, but also the myocardial involvement of COVID-19 might not be captured by the CURB-65 [@bib0008], [@bib0009], [@bib0010].

Thus, we express our concerns regarding the use of the CURB-65 to guide the decision of inpatient or outpatient care for COVID-19. There is an unmet need to have easy-to-use scores to detect COVID-19 patients at risk, and to guide this decision.
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[^1]: Results are expressed as count (%) for categorical variables and as mean (standard deviation) for quantitative variables. \*SGOT and SPOT were available for 244 (87.5%), us troponin I levels for 157 (56.3%) patients, and ferritin for 112 (29.6%) patients. Abbreviations: AST: aspartate aminotransferase; ALT: alanine aminotransferase; HFNC: high flow nasal cannula; NVI: non-invasive ventilation.
